{"type":"trials","record":{"id":41877,"source_id":"clinicaltrials-gov","external_id":"NCT05536752","title":"QA102 Phase II Study in Subjects With Dry AMD","brief_summary":"This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Smilebiotek Zhuhai Limited","enrollment":150,"countries":["United States"],"start_date":"2022-09-22","completion_date":"2024-11-12","last_update_date":"2025-01-07","source_url":"https://clinicaltrials.gov/study/NCT05536752","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"AMEND","age_range":"50 Years","comparator":"Placebo group","organization":"Smilebiotek Zhuhai Limited","interventions":["QA102/Placebo","QA102","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change from baseline in soft drusen volume (mm3) — Month 12","Change from Baseline in BCVA — Month 12","Change from Baseline in LLVA — Month 12","Change from baseline in soft drusen volume (mm3) — Month 1,2,3,6,9,12,15","Change from Baseline in BCVA — Month 1,2,3,6,9,12,15","Change from Baseline in LLVA — Month 1,2,3,6,9,12,15","Change from baseline in GA — Month 1,2,3,6,9,12,15","Mean rate of GA growth — Month 1,2,3,6,9,12,15","Area under the curve for BCVA letters — Month 1,2,3,6,9,12,15","Proportion of subjects with disease progression — Month 15","Proportion of subjects with progression of GA — Month 1,2,3,6,9,12,15","Rescue injections — Month 1,2,3,6,9,12,15","iRORA — Month 1,2,3,6,9,12,15","Fellow eye CNV — Month 1,2,3,6,9,12,15"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":false},"controlled_terms":["Dry Age-related Macular Degeneration","QA102/Placebo","QA102","Placebo"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05536752","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-09-22 to 2024-11-12","comparator":"Placebo group","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.885Z","intervention":["QA102/Placebo","QA102","Placebo"],"participants":150,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change from baseline in soft drusen volume (mm3) — Month 12","Change from Baseline in BCVA — Month 12","Change from Baseline in LLVA — Month 12","Change from baseline in soft drusen volume (mm3) — Month 1,2,3,6,9,12,15","Change from Baseline in BCVA — Month 1,2,3,6,9,12,15","Change from Baseline in LLVA — Month 1,2,3,6,9,12,15","Change from baseline in GA — Month 1,2,3,6,9,12,15","Mean rate of GA growth — Month 1,2,3,6,9,12,15","Area under the curve for BCVA letters — Month 1,2,3,6,9,12,15","Proportion of subjects with disease progression — Month 15","Proportion of subjects with progression of GA — Month 1,2,3,6,9,12,15","Rescue injections — Month 1,2,3,6,9,12,15","iRORA — Month 1,2,3,6,9,12,15","Fellow eye CNV — Month 1,2,3,6,9,12,15"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41877","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}